• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    12/27/22 12:31:55 PM ET
    $ACER
    $ATNF
    $COSM
    $FWBI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACER alert in real time by email

    Gainers

    • Quotient (NASDAQ:QTNT) shares increased by 129.0% to $0.44 during Tuesday's regular session. As of 12:30 EST, Quotient's stock is trading at a volume of 20.9 million, which is 8106.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.5 million.
    • 180 Life Sciences (NASDAQ:ATNF) stock rose 67.58% to $2.08. Trading volume for this security as of 12:30 EST is 43.9 million, which is 7441.9% of its average full-day volume over the last 100 days. The company's market cap stands at $4.2 million.
    • HTG Molecular Diagnostics (NASDAQ:HTGM) shares moved upwards by 50.81% to $4.68. As of 12:30 EST, this security is trading at a volume of 22.0 million shares, making up 4714.2% of its average full-day volume over the last 100 days. The company's market cap stands at $4.7 million.
    • First Wave BioPharma (NASDAQ:FWBI) shares moved upwards by 19.86% to $0.55. As of 12:30 EST, this security is trading at a volume of 270.2K shares, making up 37.4% of its average full-day volume over the last 100 days. The company's market cap stands at $3.2 million.
    • Virax Biolabs Group (NASDAQ:VRAX) stock increased by 19.28% to $0.68. Trading volume for this security as of 12:30 EST is 669.4K, which is 55.4% of its average full-day volume over the last 100 days. The company's market cap stands at $8.7 million.
    • KalVista Pharma (NASDAQ:KALV) stock increased by 17.02% to $5.98. The current volume of 1.0 million shares is 245.4% of KalVista Pharma's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $147.2 million.

    Losers

    • Acer Therapeutics (NASDAQ:ACER) stock declined by 35.5% to $2.4 during Tuesday's regular session. Acer Therapeutics's stock is trading at a volume of 2.1 million shares as of 12:30 EST. This is 608.2% of its average full-day volume over the last 100 days. The company's market cap stands at $46.8 million.
    • Intelligent Bio Solutions (NASDAQ:INBS) stock decreased by 20.03% to $0.23. Trading volume for Intelligent Bio Solutions's stock is 126.9K as of 12:30 EST. This is 309.4% of its average full-day volume over the last 100 days. The company's market cap stands at $4.1 million.
    • Cosmos Health (NASDAQ:COSM) stock decreased by 19.0% to $5.18. As of 12:30 EST, this security is trading at a volume of 2.1 million shares, making up 39.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $40.2 million.
    • Scopus BioPharma (NASDAQ:SCPS) stock declined by 17.83% to $0.11. Scopus BioPharma's stock is trading at a volume of 70.9K shares as of 12:30 EST. This is 7.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.2 million.
    • Yield10 Bioscience (NASDAQ:YTEN) shares decreased by 17.5% to $1.65. The company's market cap stands at $8.1 million.
    • Soligenix (NASDAQ:SNGX) stock declined by 16.84% to $0.54. Soligenix's stock is trading at a volume of 134.5K shares as of 12:30 EST. This is 169.3% of its average full-day volume over the last 100 days. The company's market cap stands at $23.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACER
    $ATNF
    $COSM
    $FWBI

    CompanyDatePrice TargetRatingAnalyst
    KalVista Pharmaceuticals Inc.
    $KALV
    1/9/2026$32.00 → $35.00Buy
    Needham
    KalVista Pharmaceuticals Inc.
    $KALV
    1/6/2026$28.00 → $32.00Buy
    Needham
    Virax Biolabs Group Limited
    $VRAX
    3/31/2025$3.00Buy
    H.C. Wainwright
    KalVista Pharmaceuticals Inc.
    $KALV
    1/31/2025$19.00Mkt Outperform
    JMP Securities
    KalVista Pharmaceuticals Inc.
    $KALV
    1/7/2025$30.00Buy
    TD Cowen
    KalVista Pharmaceuticals Inc.
    $KALV
    12/18/2024$22.00Buy
    BofA Securities
    Yield10 Bioscience Inc.
    $YTEN
    2/8/2024Buy → Hold
    Lake Street
    KalVista Pharmaceuticals Inc.
    $KALV
    3/11/2022$48.00 → $42.00Buy
    Needham
    More analyst ratings

    $ACER
    $ATNF
    $COSM
    $FWBI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ACER
    $ATNF
    $COSM
    $FWBI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000

    CHICAGO, March 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the purchase of $600,000 of Bitcoin as part of its ongoing digital assets treasury initiative. Following this purchase, Cosmos Health's total investment in digital assets has reached $3.1 million, reflecting the combined value of its holdings in Bitcoin and Ethereum. Greg Siokas, CEO of Cosmos Health, stated: "We continue to view select digital assets as an attractive asset class with strong upside potential. Our growing position in Bitcoin and Ethereum reflects a disciplined treasury strategy design

    3/11/26 1:45:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000

    CHICAGO, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has entered into a Letter of Intent ("LOI"), through its wholly owned subsidiary CosmoFarm S.A. ("CosmoFarm"), with respect to the acquisition of an extensive pharmacy distribution network from an established pharmaceutical company serving the Greek market for almost 40 years. The term of the LOI is ninety (90) days from March 6, 2026. The network currently generates approximately €10 million (approximately $11.5 million based on the prevailing EUR/USD exchange rate) in annual gross reve

    3/10/26 9:00:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

    PRINCETON, N.J., March 10, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the United Kingdom (UK) by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of Behçet's Disease. The PIM designation is the first step and a prerequisite towards inclusion in the UK Early

    3/10/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ATNF
    $COSM
    $FWBI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $35.00 from $32.00 previously

    1/9/26 7:49:25 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $28.00 previously

    1/6/26 7:58:35 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Virax Biolabs Group Ltd. with a new price target

    H.C. Wainwright initiated coverage of Virax Biolabs Group Ltd. with a rating of Buy and set a new price target of $3.00

    3/31/25 8:25:16 AM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACER
    $ATNF
    $COSM
    $FWBI
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Virax Biolabs Group Limited

    SCHEDULE 13G - Virax Biolabs Group Ltd (0001885827) (Subject)

    2/17/26 9:42:16 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Soligenix Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - SOLIGENIX, INC. (0000812796) (Filer)

    2/12/26 4:05:19 PM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Virax Biolabs Group Limited

    6-K - Virax Biolabs Group Ltd (0001885827) (Filer)

    1/30/26 4:01:50 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACER
    $ATNF
    $COSM
    $FWBI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for OLPRUVA issued to ACER THERAPEUTICS INC

    Submission status for ACER THERAPEUTICS INC's drug OLPRUVA (ORIG-1) with active ingredient SODIUM PHENYLBUTYRATE has changed to 'Approval' on 12/22/2022. Application Category: NDA, Application Number: 214860, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/23/22 1:58:04 PM ET
    $ACER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ATNF
    $COSM
    $FWBI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by KalVista Pharmaceuticals Inc.

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    3/10/26 6:47:33 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 11,250 shares and sold $83,345 worth of shares (5,354 units at $15.57), increasing direct ownership by 4% to 138,983 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/24/26 7:44:46 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 23,250 shares and sold $156,197 worth of shares (10,034 units at $15.57), increasing direct ownership by 3% to 442,883 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/24/26 7:44:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ATNF
    $COSM
    $FWBI
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. "I am pleased to welcome Bilal and Linea to our leadership team as we advance the global launch of EKTERLY," said Ben Palleiko, Chief Executive Officer of KalVista. "Their respective expertise in operations and human resources will be instrumental as we deliver on our commitment to people living with HAE." "I am excited to join KalVista and collaborate with such a talented team," said Mr. Arif. "This is a pivotal time for EKTERLY, and I am focused on strengthening the operational framework to ensure pe

    10/6/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointment of Bethany L. Sensenig to its Board of Directors, effective as of October 1, 2025. Ms. Sensenig was also appointed a member of the Audit Committee of the Board. In connection with Ms. Sensenig's appointment to the Audit Committee, Nancy Stuart will transition off the Audit Committee but remains a member of the Board and continues to serve on the Nominating and Corporate Governance Committee of the Board. The Board also approved Ms. Stuart's appointment to the Compensation Committee of the Board. "I am pleased to welcome Bethany to the Board of Directors of KalVista. Her extensive financial and operational experti

    10/2/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ATNF
    $COSM
    $FWBI
    Financials

    Live finance-specific insights

    View All

    KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

    US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE) Launched EKTERLY in Germany with initial orders signaling encouraging demand $309M in cash expected to fund the Company through profitability Management to host conference call Tuesday, November 11th at 8:30 a.m. ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025. "The US launch of EKTERLY is progressing with si

    11/10/25 4:30:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review the Company's third quarter financial results and provide an operational update. The live audio webcast will be accessible on the Investors section of the Company's website at www.ir.kalvista.com/event-calendar. An archived replay will be available on the site approximately two hours after completion of the event. About KalVista Pharmaceuticals, Inc. KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered

    11/3/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

    -EKTERLY® now approved in the US and UK; first and only oral on-demand therapy for acute attacks of hereditary angioedema- -Initiated US EKTERLY launch in July; received 460 patient start forms through August- -European Medicines Agency adopted a positive opinion recommending approval of sebetralstat and confirmed maintenance of orphan designation in EU; decision expected early October- -$191M in cash, providing runway into 2027- -Management to host conference call today at 8:30 a.m. ET- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and released financial results for the fiscal quarter ended July 31, 2025. "This quarter marked a defining mome

    9/11/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ATNF
    $COSM
    $FWBI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

    SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

    11/14/24 4:50:24 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Virax Biolabs Group Limited

    SC 13G/A - Virax Biolabs Group Ltd (0001885827) (Subject)

    11/14/24 4:46:07 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

    SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

    11/14/24 4:00:06 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care